New combo diabetes pill passes early safety check in healthy people
NCT ID NCT07128654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new combination pill (CTL02) that contains two diabetes drugs (alogliptin and empagliflozin) in a single tablet. Forty healthy adults received either the combo pill or the two drugs separately to compare safety and how the body processes them. The trial is complete and focused on basic safety and drug levels, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CTL02 (a fixed-dose combination tablet of alogliptin and empagliflozin)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H+ Yangji Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test